8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Jan 7, 2026·SEC
Immuneering Corporation(IMRX)Earnings, Financials & Key Ratios
IMRX•NASDAQ
Price updated Jun 11, 2026
AboutImmuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.Show more
- Revenue$0
- EBITDA-$59M+7.9%
- Net Income-$56M+8.2%
- EPS (Diluted)-1.27+37.7%
- ROE-43.12%+53.4%
- ROIC-86.41%+59.5%
- Debt/Equity0.02-82.6%
IMRX Key Insights
Immuneering Corporation (IMRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Profits declining 26.9% over 5 years
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 46.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMRX Price & Volume
Immuneering Corporation (IMRX) stock price & volume — 10-year historical chart
Loading chart...
IMRX Growth Metrics
Immuneering Corporation (IMRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.31%
Return on Capital
10 Years-54.11%
5 Years-52.77%
3 Years-63.97%
Last Year-44.46%
IMRX Recent Earnings
Immuneering Corporation (IMRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 15, 2026EPS
$0.21
Est $0.30
+30.0%
Revenue
—
Q2 2026
Mar 6, 2026EPS
$0.18
Est $0.31
+41.9%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.38
Est $0.37
-2.7%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.40
Est $0.40
+0.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.21vs $0.30+30.0% | — |
| Q2 2026 | Mar 6, 2026 | $0.18vs $0.31+41.9% | — |
| Q4 2025 | Nov 12, 2025 | $0.38vs $0.37-2.7% | — |
| Q3 2025 | Aug 13, 2025 | $0.40vs $0.40+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
IMRX Peer Comparison
Immuneering Corporation (IMRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 EXEL | 13.59B | 53.50 | 19.24 | 6.98% | 35.08% | 40.21% | 0.08 | |
 MGNX | 254.89M | 4.01 | -3.40 | 0.78% | -44.79% | -147.8% | 1.92 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare IMRX vs Peers
Immuneering Corporation (IMRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMRX Income Statement
Immuneering Corporation (IMRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.92M | 2.31M | 2.08M | 316.95K | 0 | 0 | 0 | 0 |
Revenue Growth % | - | 20.41% | -10.02% | -84.76% | -100% | - | - | - |
Cost of Goods Sold | 1.22M | 1.28M | 1.15M | 158.12K | 0 | 0 | 698.89K | 793.21K |
COGS % of Revenue | 63.71% | 55.39% | 55.44% | 49.89% | - | - | - | - |
Gross Profit | 696.74K▲ 0% | 1.03M▲ 48.0% | 926.89K▼ 10.1% | 158.83K▼ 82.9% | 0▼ 100.0% | 0▲ 0% | -698.89K▲ 0% | -793.21K▲ 0% |
Gross Margin % | 36.29% | 44.61% | 44.56% | 50.11% | - | - | - | - |
Gross Profit Growth % | - | 48.01% | -10.12% | -82.86% | -100% | - | - | - |
Operating Expenses | 6.99M | 18.11M | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M | 58.43M |
OpEx % of Revenue | 364% | 783.62% | 1673.73% | 16375.89% | - | - | - | - |
Selling, General & Admin | 2.71M | 3.11M | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M | 4.7B |
SG&A % of Revenue | 141.11% | 134.54% | 397.7% | 4924.09% | - | - | - | - |
Research & Development | 4.28M | 15M | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M | 10.68B |
R&D % of Revenue | 222.89% | 649.08% | 1276.03% | 11442.46% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 29.58K | 28.87K | 29.01K | -669.62K | -1.67M |
Operating Income | -6.29M▲ 0% | -17.08M▼ 171.5% | -33.89M▼ 98.4% | -51.74M▼ 52.7% | -58.41M▼ 12.9% | -64.07M▼ 9.7% | -59.38M▲ 7.3% | -59.23M▲ 0% |
Operating Margin % | -327.71% | -739.01% | -1629.17% | -16325.77% | - | - | - | - |
Operating Income Growth % | - | -171.54% | -98.37% | -52.7% | -12.89% | -9.69% | 7.33% | - |
EBITDA | -6.27M | -17M | -33.73M | -51.47M | -58.06M | -63.69M | -58.68M | -58.44M |
EBITDA Margin % | -326.76% | -735.58% | -1621.52% | -16238.3% | - | - | - | - |
EBITDA Growth % | - | -171.06% | -98.36% | -52.6% | -12.81% | -9.69% | 7.87% | 8.36% |
D&A (Non-Cash Add-back) | 18.08K | 79.31K | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K | 786.79K |
EBIT | -7.36M | -17.08M | -33.89M | -51.75M | -58.41M | -64.07M | -59.38M | -59.64M |
Net Interest Income | -293.64K | 42.66K | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M | -411.45M |
Interest Income | 57.66K | 42.66K | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M | -411.45M |
Interest Expense | 351.3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.42M | -41.7K | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M | 4.79M |
Pretax Income | -7.71M▲ 0% | -17.12M▼ 122.1% | -33.84M▼ 97.6% | -50.51M▼ 49.3% | -53.47M▼ 5.9% | -61.04M▼ 14.1% | -56.02M▲ 8.2% | -54.44M▲ 0% |
Pretax Margin % | -401.59% | -740.82% | -1627.11% | -15937.44% | - | - | - | - |
Income Tax | 0 | -84.34K | -307.49K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0.49% | 0.91% | 0% | 0% | 0% | 0% | 0% |
Net Income | -7.71M▲ 0% | -17.04M▼ 121.0% | -33.54M▼ 96.8% | -50.51M▼ 50.6% | -53.47M▼ 5.9% | -61.04M▼ 14.1% | -56.02M▲ 8.2% | -54.44M▲ 0% |
Net Margin % | -401.59% | -737.17% | -1612.33% | -15937.29% | - | - | - | - |
Net Income Growth % | - | -121.03% | -96.81% | -50.63% | -5.86% | -14.15% | 8.21% | 11.87% |
Net Income (Continuing) | -7.71M | -17.04M | -33.54M | -50.51M | -53.47M | -61.04M | -56.02M | -54.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.60▲ 0% | -1.26▼ 110.0% | -1.27▼ 0.8% | -1.87▼ 47.2% | -1.88▼ 0.5% | -2.04▼ 8.5% | -1.27▲ 37.7% | -1.24▲ 0% |
EPS Growth % | - | -110% | -0.79% | -47.24% | -0.53% | -8.51% | 37.75% | 40.31% |
EPS (Basic) | -0.60 | -1.26 | -1.27 | -1.87 | -1.88 | -2.04 | -1.27 | - |
Diluted Shares Outstanding | 13.51M | 13.51M | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M | 44.01M |
Basic Shares Outstanding | 13.51M | 13.51M | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M | 44.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IMRX Balance Sheet
Immuneering Corporation (IMRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.06M | 37.73M | 152.33M | 108.75M | 89.08M | 39.59M | 176.25M | 161.41B |
Cash & Short-Term Investments | 13.78M | 37.09M | 149.2M | 105.52M | 85.67M | 36.14M | 172.83M | 156.69B |
Cash Only | 13.78M | 37.09M | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M | 47.32B |
Short-Term Investments | 0 | 0 | 74.31M | 32.89M | 26.26M | 0 | 44.19M | 109.37B |
Accounts Receivable | 209.94K | 500.11K | 246.04K | 12.42K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 39.92 | 78.97 | 43.18 | 14.3 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 3.21M | 3.42M | 3.44M | 3.41M | 4.72B |
Total Non-Current Assets | 35.28K | 691.8K | 14.37M | 13.62M | 13.5M | 13.13M | 55.74M | 53.4B |
Property, Plant & Equipment | 35.28K | 677.47K | 6.13M | 5.78M | 5.4M | 4.79M | 4.26M | 4.17B |
Fixed Asset Turnover | 54.42x | 3.41x | 0.34x | 0.05x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 6.7M | 6.69M | 6.69M | 6.69M | 6.69M | 6.69B |
Intangible Assets | 0 | 0 | 439K | 408.95K | 379.68K | 350.41K | 321.15K | 313.83M |
Long-Term Investments | 0 | 0 | 996.56K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 14.33K | 102.13K | 743.7K | 1.03M | 1.3M | 44.47M | 42.23B |
Total Assets | 14.1M▲ 0% | 38.42M▲ 172.5% | 166.7M▲ 333.9% | 122.37M▼ 26.6% | 102.58M▼ 16.2% | 52.71M▼ 48.6% | 231.99M▲ 340.1% | 214.81B▲ 0% |
Asset Turnover | 0.14x | 0.06x | 0.01x | 0.00x | - | - | - | 0.00x |
Asset Growth % | - | 172.53% | 333.87% | -26.6% | -16.17% | -48.61% | 340.08% | 424287.96% |
Total Current Liabilities | 505.3K | 2.26M | 5.63M | 8.05M | 7.85M | 7.5M | 10.07M | 4.97B |
Accounts Payable | 294.95K | 1.48M | 1.39M | 3.15M | 2.11M | 1.96M | 1.54M | 1.45B |
Days Payables Outstanding | 88.03 | 422.08 | 441.37 | 7.28K | - | - | 805.71 | 167.81K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 397.1K | 412.83M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 118.72K | 163.67K | 2.92M | 3.65M | 3.89M | 3.82M | 8.13M | 3.11B |
Current Ratio | 27.83x | 16.73x | 27.04x | 13.50x | 11.35x | 5.28x | 17.50x | 32.45x |
Quick Ratio | 27.83x | 16.73x | 27.04x | 13.50x | 11.35x | 5.28x | 17.50x | 32.45x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 20.12M | 58.65M | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M | 3.32B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.32B |
Capital Lease Obligations | 0 | 544.77K | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M | 10.6M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20.12M | 58.1M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20.63M | 60.9M | 10.72M | 12.52M | 12.01M | 11.33M | 13.5M | 8.29B |
Total Debt | 0 | 621.09K | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M | 3.73B |
Net Debt | -13.78M | -36.47M | -69.52M | -67.8M | -54.94M | -31.98M | -124.82M | -43.59B |
Debt / Equity | - | - | 0.03x | 0.04x | 0.05x | 0.10x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | -63.83x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 745.92x |
Interest Coverage | -20.95x | - | - | - | - | - | - | - |
Total Equity | -6.53M▲ 0% | -22.48M▼ 244.4% | 155.98M▲ 793.8% | 109.85M▼ 29.6% | 90.58M▼ 17.5% | 41.39M▼ 54.3% | 218.48M▲ 427.9% | 206.52B▲ 0% |
Equity Growth % | - | -244.38% | 793.82% | -29.57% | -17.55% | -54.31% | 427.91% | 494122.35% |
Book Value per Share | -0.48 | -1.66 | 5.93 | 4.16 | 3.19 | 1.38 | 4.96 | 4692.33 |
Total Shareholders' Equity | -6.53M | -22.48M | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M | 206.52B |
Common Stock | 4.95K | 4.95K | 26.32K | 26.42K | 29.27K | 31.05K | 64.65K | 64.69M |
Retained Earnings | -8.7M | -25.74M | -59.27M | -109.79M | -163.26M | -224.3M | -280.32M | -293.78B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -49.01K | -30.12K | -778 | 0 | 81.33K | -241M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMRX Cash Flow Statement
Immuneering Corporation (IMRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.44M | -14.62M | -30.85M | -44.1M | -48.97M | -55M | -45.34M | -49.7M |
Operating CF Margin % | -231.41% | -632.52% | -1483.24% | -13914.18% | - | - | - | - |
Operating CF Growth % | - | -229.11% | -111.01% | -42.95% | -11.04% | -12.32% | 17.55% | 30.41% |
Net Income | -7.71M | -17.04M | -33.54M | -50.51M | -53.47M | -61.04M | -56.02M | -54.44M |
Depreciation & Amortization | 18.08K | 79.31K | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K | 531.13K |
Stock-Based Compensation | 596.63K | 1.09M | 1.8M | 0 | 5.73M | 6.5M | 0 | 1.52M |
Deferred Taxes | 0 | 0 | -307.49K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.22M | 0 | 130.24K | 3.9M | -601.59K | 75.98K | 6.16M | 4.34M |
Working Capital Changes | 437.13K | 1.25M | 900.42K | 1.72M | -974.64K | -925.38K | 3.82M | -1.66M |
Change in Receivables | 614.11K | -290.17K | 279.71K | 233.62K | 12.42K | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 270.5K | 1.19M | -130.4K | 1.76M | -1.11M | -112.14K | -400.8K | 197.49K |
Cash from Investing | -20.53K | -53.41K | -75.62M | 41.83M | 7.3M | 26.43M | -88.74M | -151.8M |
Capital Expenditures | -20.53K | -53.41K | -60.79K | -742.48K | -342.75K | -84.88K | -142.23K | -213.21K |
CapEx % of Revenue | 1.07% | 2.31% | 2.92% | 234.26% | - | - | - | - |
Acquisitions | 0 | 0 | 70.35K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -75.62M | 0 | 0 | 0 | 247 | 0 |
Cash from Financing | 17.17M | 37.98M | 144.26M | 19K | 28.44M | 5.3M | 226.58M | 212.95M |
Debt Issued (Net) | 3.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 13.4M | 37.98M | 145.11M | 19K | 28.2M | 4.24M | 226.58M | 212.95M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -56.24K | 0 | -842.76K | 0 | 241.07K | 1.07M | -147 | 0 |
Net Change in Cash | 12.71M▲ 0% | 23.31M▲ 83.4% | 37.8M▲ 62.2% | -2.25M▼ 106.0% | -13.23M▼ 487.7% | -23.26M▼ 75.8% | 92.5M▲ 497.7% | 11.46M▲ 0% |
Free Cash Flow | -4.46M▲ 0% | -14.67M▼ 228.8% | -30.91M▼ 110.7% | -44.84M▼ 45.1% | -49.31M▼ 10.0% | -55.08M▼ 11.7% | -45.49M▲ 17.4% | -49.91M▲ 0% |
FCF Margin % | -232.48% | -634.83% | -1486.17% | -14148.44% | - | - | - | - |
FCF Growth % | - | -228.8% | -110.65% | -45.07% | -9.96% | -11.71% | 17.42% | 6.96% |
FCF per Share | -0.33 | -1.09 | -1.17 | -1.70 | -1.74 | -1.84 | -1.03 | -1.13 |
FCF Conversion (FCF/Net Income) | 0.58x | 0.86x | 0.92x | 0.87x | 0.92x | 0.90x | 0.81x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMRX Key Ratios
Immuneering Corporation (IMRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -50.24% | -38% | -53.36% | -92.51% | -43.12% | -0.11% |
| Return on Invested Capital (ROIC) | - | -184.79% | -60.4% | -112.78% | -213.39% | -86.41% | -0.11% |
| Gross Margin | 44.61% | 44.56% | 50.11% | - | - | - | - |
| Net Margin | -737.17% | -1612.33% | -15937.29% | - | - | - | - |
| Debt / Equity | - | 0.03x | 0.04x | 0.05x | 0.10x | 0.02x | 0.02x |
| FCF Conversion | 0.86x | 0.92x | 0.87x | 0.92x | 0.90x | 0.81x | 0.92x |
| Revenue Growth | 20.41% | -10.02% | -84.76% | -100% | - | - | - |
Related:IMRX Dividend History·IMRX Revenue History·IMRX Price History·IMRX P/E History·IMRX Financial Ratios·IMRX Institutional Holders
IMRX SEC Filings & Documents
Immuneering Corporation (IMRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMRX Frequently Asked Questions
Immuneering Corporation (IMRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immuneering Corporation (IMRX) grew revenue by 0.0% over the past year. Growth has been modest.
Immuneering Corporation (IMRX) reported a net loss of $54.4M for fiscal year 2025.
Dividend & Returns
Immuneering Corporation (IMRX) has a return on equity (ROE) of -43.1%. Negative ROE indicates the company is unprofitable.
Immuneering Corporation (IMRX) had negative free cash flow of $49.9M in fiscal year 2025, likely due to heavy capital investments.